The endogenous mechanisms for the regulation of blood coagulation include the inhibition of coagulation enzymes, the inactivation of coagulation co-factors and clearance mechanisms for the enzymes and co- factors. One key regulatory inhibitor of coagulation is tissue factor pathway inhibitor (TFPI), which produces feedback inhibition of the factor VIIa/tissue factor complex and directly binds and inhibits factor Xa. TFPI is rapidly cleared in vivo via the endocytosis receptor, LRP (low density lipoprotein receptor-related protein). LPR governs the endocytosis of a wide variety of ligands which share an important role in regulation of blood coagulation/fibrinolysis. In addition, a 39 kDa protein serves both as a ligand for LRP and as an inhibitor of LRP function. In addition to LRP, TFPI interacts with cell surface heparan sulfate proteoglycans (HSPGs) which function as a second class of clearance receptors. Recently, we have described a new clearance receptor system, also involving cell surface HSPGs, which recognizes TFPI in the context of factor Xa Thus, our specific aims focus on elucidation of the molecular mechanisms responsible for the rapid clearance of TFPI both in vitro and in vivo. We have available a variety of cell lines which mediate TFPI uptake-degradation as antibodies to each protein, HSPG mutant cells as well as mutant (knockout and over-expression) mice. We shall (1) define the structural features of TFPI which mediate LRP recognition using TFPI mutants, LRP mini-receptors, and sensitive binding/competition assays; (2) identify the HSPG species which serves as the TFPI cell surface receptor in vitro using cell lines, homozygous deficient or over- expressing each of the six glypicans and in vivo using the various glypican (-/-) mice; (3) identify the TFPI-Xa receptor using a series of cell biological approaches including affinity chromatography, expression cloning, expression cloning. These studies will thus provide a basis for elucidating the molecular mechanisms by which blood coagulation proteins are endogenously regulated.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL053280-09
Application #
6628973
Study Section
Hematology Subcommittee 2 (HEM)
Program Officer
Link, Rebecca P
Project Start
1995-01-15
Project End
2005-01-31
Budget Start
2003-02-01
Budget End
2005-01-31
Support Year
9
Fiscal Year
2003
Total Cost
$257,627
Indirect Cost
Name
Washington University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Melman, Lora; Geuze, Hans J; Li, Yonghe et al. (2002) Proteasome regulates the delivery of LDL receptor-related protein into the degradation pathway. Mol Biol Cell 13:3325-35
Obermoeller-McCormick, L M; Li, Y; Osaka, H et al. (2001) Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptor-related protein. J Cell Sci 114:899-908
Liu, C X; Li, Y; Obermoeller-McCormick, L M et al. (2001) The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein. J Biol Chem 276:28889-96
Narita, M; Rudolph, A E; Miletich, J P et al. (1998) The low-density lipoprotein receptor-related protein (LRP) mediates clearance of coagulation factor Xa in vivo. Blood 91:555-60
Mast, A E; Higuchi, D A; Huang, Z F et al. (1997) Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. Biochem J 327 ( Pt 2):577-83
Warshawsky, I; Herz, J; Broze Jr, G J et al. (1996) The low density lipoprotein receptor-related protein can function independently from heparan sulfate proteoglycans in tissue factor pathway inhibitor endocytosis. J Biol Chem 271:25873-9
Warshawsky, I; Schwartz, A L (1996) The 39-kDa protein regulates LRP activity in cultured endothelial and smooth muscle cells. Eur J Cell Biol 69:156-65
Warshawsky, I; Bu, G; Mast, A et al. (1995) The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 95:1773-81
Narita, M; Bu, G; Olins, G M et al. (1995) Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem 270:24800-4
Bu, G; Geuze, H J; Strous, G J et al. (1995) 39 kDa receptor-associated protein is an ER resident protein and molecular chaperone for LDL receptor-related protein. EMBO J 14:2269-80

Showing the most recent 10 out of 13 publications